Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1016/j.annonc.2020.04.010

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

..., Laurence Albiges
60
Annals of Oncology50.50
Volume: 31, Issue: 8, Pages: 1030 - 1039
Published: Aug 1, 2020
Abstract
The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We report updated efficacy data from the second interim analysis.Treatment-naive patients with aRCC were randomized (1 : 1) to receive avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or...
Paper Fields
Paper Details
Title
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
DOI
doi.org/10.1016/j.annonc.2020.04.010
Published Date
Aug 1, 2020
Journal
Annals of Oncology
Volume
31
Issue
8
Pages
1030 - 1039
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.